NASDAQ:FENC Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free FENC Stock Alerts $9.21 +0.05 (+0.55%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$9.04▼$9.3050-Day Range$8.82▼$11.1252-Week Range$6.30▼$11.92Volume154,291 shsAverage Volume115,585 shsMarket Capitalization$249.59 millionP/E RatioN/ADividend YieldN/APrice Target$17.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Fennec Pharmaceuticals alerts: Email Address Fennec Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside88.2% Upside$17.33 Price TargetShort InterestBearish8.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 7 Articles This WeekInsider TradingSelling Shares$1.96 M Sold Last QuarterProj. Earnings Growth536.36%From $0.11 to $0.70 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector420th out of 913 stocksBiological Products, Except Diagnostic Industry65th out of 145 stocks 3.5 Analyst's Opinion Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.08% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently increased by 3.31%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FENC. Previous Next 3.0 News and Social Media Coverage News SentimentFennec Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Fennec Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for FENC on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,962,775.00 in company stock.Percentage Held by Insiders11.25% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to grow by 536.36% in the coming year, from $0.11 to $0.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is -15.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is -15.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Fennec Pharmaceuticals Stock (NASDAQ:FENC)Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More FENC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FENC Stock News HeadlinesApril 23, 2024 | insidertrades.comAdrian Haigh Sells 22,223 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) StockApril 23, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 SharesApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 19, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $220,220.02 in StockApril 18, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $228,886.60 in StockApril 6, 2024 | insidertrades.comInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells 44,300 Shares of StockApril 5, 2024 | insidertrades.comRosty Raykov Sells 40,584 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) StockMarch 28, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $23,190.58 in StockApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 20, 2024 | investing.comFennec Pharmaceuticals COO sells shares worth over $536kApril 20, 2024 | americanbankingnews.comAdrian Haigh Sells 22,222 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) StockApril 9, 2024 | finance.yahoo.comThose who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136%April 7, 2024 | uk.investing.comFennec Pharmaceuticals CEO sells shares worth over $950kApril 4, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial OutlookMarch 27, 2024 | finance.yahoo.comChief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC)March 26, 2024 | finance.yahoo.comChief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC)March 22, 2024 | markets.businessinsider.comBuy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion PotentialMarch 22, 2024 | finance.yahoo.comQ4 2023 Fennec Pharmaceuticals Inc Earnings CallMarch 21, 2024 | investorplace.comFENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023March 21, 2024 | globenewswire.comFennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | bizjournals.comRTP firm inks licensing deal for European drug launchMarch 19, 2024 | globenewswire.comFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024March 17, 2024 | globenewswire.comFennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New ZealandMarch 16, 2024 | finance.yahoo.comFENC Apr 2024 12.500 callMarch 14, 2024 | msn.comNearly 1,000 Family Dollar stores are closing, owner Dollar Tree announcesMarch 13, 2024 | nz.finance.yahoo.com'Milli Vanilli' Review: A Captivating and Moving DocumentaryMarch 13, 2024 | finance.yahoo.comAnalysts Are Optimistic We'll See A Profit From Fennec Pharmaceuticals Inc. (NASDAQ:FENC)See More Headlines Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$17.33 High Stock Price Target$18.00 Low Stock Price Target$16.00 Potential Upside/Downside+88.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E Ratio83.73 P/E GrowthN/ANet Income$-16,050,000.00 Net Margins-75.50% Pretax Margin-75.52% Return on EquityN/A Return on Assets-73.64% Debt Debt-to-Equity RatioN/A Current Ratio3.56 Quick Ratio3.27 Sales & Book Value Annual Sales$21.25 million Price / Sales11.75 Cash FlowN/A Price / Cash FlowN/A Book Value($0.43) per share Price / Book-21.42Miscellaneous Outstanding Shares27,100,000Free Float24,051,000Market Cap$249.59 million OptionableOptionable Beta0.38 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Rostislav Raykov (Age 42)Pres, CEO & Director Mr. Robert C. Andrade (Age 43)Chief Financial Officer Mr. Mark GowlandControllerMr. Lei FangPres of Pharstat IncMs. Anne McKay (Age 64)Regulatory Consultant Key CompetitorsCoherus BioSciencesNASDAQ:CHRSBlack Diamond TherapeuticsNASDAQ:BDTXMetagenomiNASDAQ:MGXSutro BiopharmaNASDAQ:STROInvivydNASDAQ:IVVDView All CompetitorsInsiders & InstitutionsEudaimonia Advisors LLCBought 2,673 shares on 4/25/2024Ownership: 0.130%Adrian HaighSold 22,223 sharesTotal: $207,118.36 ($9.32/share)Adrian HaighSold 22,222 sharesTotal: $207,553.48 ($9.34/share)Adrian HaighSold 22,222 sharesTotal: $220,220.02 ($9.91/share)Chris A RallisSold 800 sharesTotal: $8,360.00 ($10.45/share)View All Insider TransactionsView All Institutional Transactions FENC Stock Analysis - Frequently Asked Questions Should I buy or sell Fennec Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares. View FENC analyst ratings or view top-rated stocks. What is Fennec Pharmaceuticals' stock price target for 2024? 3 brokers have issued twelve-month target prices for Fennec Pharmaceuticals' shares. Their FENC share price targets range from $16.00 to $18.00. On average, they predict the company's share price to reach $17.33 in the next year. This suggests a possible upside of 88.2% from the stock's current price. View analysts price targets for FENC or view top-rated stocks among Wall Street analysts. How have FENC shares performed in 2024? Fennec Pharmaceuticals' stock was trading at $11.22 at the beginning of 2024. Since then, FENC shares have decreased by 17.9% and is now trading at $9.21. View the best growth stocks for 2024 here. Are investors shorting Fennec Pharmaceuticals? Fennec Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,810,000 shares, an increase of 7.1% from the March 15th total of 1,690,000 shares. Based on an average daily volume of 110,600 shares, the short-interest ratio is presently 16.4 days. Currently, 9.1% of the shares of the stock are sold short. View Fennec Pharmaceuticals' Short Interest. When is Fennec Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FENC earnings forecast. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by $0.12. The business had revenue of $9.74 million for the quarter, compared to analysts' expectations of $9.47 million. What guidance has Fennec Pharmaceuticals issued on next quarter's earnings? Fennec Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20.7 million-$21.2 million, compared to the consensus revenue estimate of $19.6 million. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL). Who are Fennec Pharmaceuticals' major shareholders? Fennec Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Eudaimonia Advisors LLC (0.13%). Insiders that own company stock include Adrian Haigh, Chris A Rallis, Robert Andrade and Rosty Raykov. View institutional ownership trends. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FENC) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
